美国食品和药物管理局批准了Optivo加上化疗治疗晚期霍奇金淋巴瘤,改善生存率并降低进展风险. FDA approves Opdivo plus chemo for advanced Hodgkin lymphoma, improving survival and reducing progression risk.

美国食品和药物管理局批准了Opdivo (尼沃卢马布) 加化学疗法作为12岁及以上的成人和青少年进行高级经典霍奇金淋巴瘤的一线治疗. The FDA has approved Opdivo (nivolumab) plus chemotherapy (AVD) as first-line treatment for adults and teens aged 12 and older with advanced classical Hodgkin lymphoma. 根据994名患者的试验,该结合治疗与标准疗法相比显著改善了无进展生存率和整体存活率,疾病进展或死亡风险降低了58%. The decision, based on a trial of 994 patients, showed the combination significantly improved progression-free survival and overall survival compared to standard therapy, with a 58% lower risk of disease progression or death. 39% 的患者出现严重副作用,其中9% 患有免疫相关反应. Serious side effects occurred in 39% of patients, including immune-related reactions in 9%. 这项批准标志着对早期治疗的免疫疗法进行转变. The approval marks a shift toward using immunotherapy earlier in treatment.